<?xml version="1.0" encoding="UTF-8"?>
<p id="para0006">In 2016, remdesivir (GS-5734) was reported to be active against Ebola virus in multiple human cell types, including primary macrophages and human endothelial cells, with low half-maximal effective concentration (EC
 <sub>50</sub>) values of 0.06–0.14 μM 
 <xref rid="bib0015" ref-type="bibr">[15]</xref>. In addition, remdesivir was reported to exhibit antiviral activity in vitro against Marburg virus 
 <xref rid="bib0015" ref-type="bibr">[15]</xref>, Paramyxoviridae (such as parainfluenza type 3 virus, Nipah virus, Hendra virus, and measles and mumps viruses) and Pneumoviridae (such as respiratory syncytial virus) 
 <xref rid="bib0019" ref-type="bibr">[19]</xref>.
</p>
